Issuer directory · Pharmaceuticals · page 2
Pharmaceuticals: issuers 101 to 184 of 184.
Ranked by the amount reported sold on the newest Form D. Page 1 holds the largest raises in the group.
| Issuer | Reported sold | Investors | Exemption | Newest notice | Filings | Platform |
|---|---|---|---|---|---|---|
| Windgap Medical, Inc. | $12.7M | 13 | 506(b) | Jan 26, 2026 | 2 | direct |
| TELYRX HOLDINGS INC. | $12.6M | 51 | 506(b) | Apr 20, 2026 | 1 | direct |
| TelyRx Finco Inc. | $12.6M | 51 | 506(b) | Apr 20, 2026 | 1 | direct |
| Retension Pharmaceuticals, Inc. | $12.3M | 98 | 506(b) | May 6, 2025 | 1 | direct |
| TearClear Corp. | $11.8M | 70 | 506(b) | Jul 13, 2023 | 1 | direct |
| Medsyn Biopharma LLC | $11.5M | 16 | 506(b) | Nov 4, 2025 | 1 | direct |
| Pharmaceutics International, Inc. | $11.2M | 3 | 506(b) | Oct 23, 2024 | 2 | direct |
| Octagon Therapeutics, Inc. | $11.0M | 53 | 506(b) | Feb 12, 2024 | 1 | direct |
| General Oncology, Inc. | $10.9M | 43 | 506(b) | Jul 2, 2025 | 9 | direct |
| Hallux, Inc. | $10.7M | 18 | 506(b) | Apr 26, 2023 | 2 | direct |
| Sprout2 Inc. | $10.6M | 51 | 506(b) | Dec 23, 2024 | 1 | direct |
| Lucy Therapeutics, Inc. | $10.6M | 6 | 506(b) | May 2, 2024 | 2 | direct |
| Cyclarity Therapeutics, Inc. | $10.3M | 19 | 506(b) | Dec 30, 2024 | 1 | direct |
| Athos Therapeutics, Inc. | $10.3M | 40 | 506(b) | May 15, 2026 | 1 | direct |
| CERO THERAPEUTICS HOLDINGS, INC. | $10.2M | 46 | 506(b) | Feb 23, 2024 | 1 | direct |
| Immunophotonics, Inc. | $10.1M | 45 | 506(b) | Sep 4, 2026 | 1 | direct |
| STAQ Pharma, Inc. | $10.1M | 17 | 506(b) | Jun 21, 2023 | 2 | direct |
| BTB Therapeutics, Inc. | $8.9M | 4 | 506(b) | Aug 12, 2026 | 2 | direct |
| Nacuity Pharmaceuticals, Inc. | $8.4M | 98 | 506(b) | Dec 30, 2025 | 1 | direct |
| NBO Pharma Inc. | $7.6M | 93 | 506(c) | Jan 22, 2026 | 1 | direct |
| Pneuma Respiratory, Inc. | $7.3M | 68 | 506(b) | Dec 23, 2024 | 1 | direct |
| Clene Inc. | $7.3M | 13 | 506(b) | Oct 9, 2024 | 1 | direct |
| OS Therapies Inc | $7.1M | 34 | 506(b) | Jan 22, 2025 | 1 | direct |
| Cristcot LLC | $7.0M | 30 | 506(b) | May 1, 2024 | 1 | direct |
| Psy Therapeutics, Inc. | $6.8M | 23 | 506(b) | Sep 12, 2025 | 4 | direct |
| 65 Therapeutics, Inc. | $6.7M | 2 | 506(b) | Jul 6, 2026 | 2 | direct |
| AltrixBio, Inc. | $6.6M | 50 | 504, 506(c) | Jun 13, 2025 | 2 | direct |
| Maxona Pharmaceuticals, Inc. | $5.8M | 56 | 506(b) | Aug 14, 2026 | 2 | direct |
| PLEOPHARMA, INC. | $5.5M | 11 | 506(b) | Aug 10, 2026 | 1 | direct |
| Pharmazz, Inc. | $5.5M | 28 | 506(b) | May 18, 2023 | 2 | direct |
| Transposon Therapeutics, Inc. | $5.0M | 8 | 506(b) | Jan 12, 2023 | 2 | direct |
| Persist AI Formulations Corp | $4.9M | 27 | 506(b) | Apr 24, 2023 | 1 | direct |
| Nevakar Inc. | $4.6M | 12 | 506(b) | Aug 8, 2023 | 1 | direct |
| Aveta Biomics, Inc. | $4.5M | 36 | 506(b) | Mar 19, 2025 | 1 | direct |
| Endolytix Technology, Inc. | $4.3M | 14 | 504, 506(b) | Sep 13, 2023 | 2 | direct |
| Duo Oncology Inc. | $4.3M | 14 | 506(b) | Aug 11, 2023 | 2 | direct |
| Natsar Pharmaceuticals, Inc. | $4.2M | 15 | 506(b) | May 8, 2026 | 1 | direct |
| Insigna, Inc. | $4.0M | 2 | 506(b) | Jul 8, 2025 | 2 | direct |
| Response Pharmaceuticals, Inc. | $3.9M | 51 | 506(b) | Jun 28, 2024 | 1 | direct |
| 2A Biosciences, Inc. | $3.8M | 13 | 506(b) | Jul 27, 2023 | 2 | direct |
| Zurex Pharma, Inc. | $3.8M | 14 | 506(b) | Dec 29, 2023 | 1 | direct |
| M Chest Institutional Pharmacy Group, LLC | $3.7M | 15 | 506(b) | Mar 1, 2024 | 1 | direct |
| Biodexa Pharmaceuticals Plc | $3.3M | 15 | 506(b) | Jun 7, 2023 | 1 | direct |
| Balanced Pharma Inc | $3.2M | 1 | 506(b) | Sep 23, 2025 | 2 | direct |
| Illudent, Inc. | $3.2M | 11 | 506(b) | Aug 15, 2025 | 1 | direct |
| LivFul Inc. | $3.1M | 13 | 506(b) | Apr 5, 2023 | 2 | direct |
| Rhoshan Pharmaceuticals, Inc. | $3.1M | 4 | 506(b) | Jul 22, 2026 | 3 | direct |
| Myosin Therapeutics Inc. | $3.0M | 4 | 506(b) | Mar 24, 2023 | 2 | direct |
| AION Healthspan, Inc. | $2.9M | 10 | 506(b) | Mar 17, 2023 | 1 | direct |
| Invirsa, Inc. | $2.9M | 14 | 506(b) | Aug 8, 2025 | 2 | direct |
| Avana Health, Inc. | $2.8M | 29 | 506(b) | Dec 19, 2025 | 1 | direct |
| Galera Therapeutics, Inc. | $2.7M | 18 | 506(b) | Jan 13, 2025 | 1 | direct |
| OWP PHARMACEUTICALS, INC. | $2.7M | 11 | 506(b) | Sep 16, 2024 | 1 | direct |
| XTRESSE, LLC | $2.7M | 30 | 506(b) | Nov 24, 2025 | 1 | direct |
| LIPELLA PHARMACEUTICALS INC. | $2.6M | 26 | 506(b) | Jan 7, 2025 | 1 | direct |
| ResBiotic Nutrition, Inc. | $2.5M | 1 | 506(b) | Sep 17, 2025 | 2 | direct |
| Pierrepont Therapeutics, Inc. | $2.4M | 2 | 506(b) | Sep 22, 2026 | 2 | direct |
| Acurx Pharmaceuticals, Inc. | $2.4M | 12 | 506(b) | Jan 17, 2025 | 1 | direct |
| Indaptus Therapeutics, Inc. | $2.3M | 20 | 506(c) | Jun 20, 2025 | 1 | direct |
| Aviv Pharma Inc. | $2.3M | 12 | 506(c) | Dec 28, 2023 | 1 | direct |
| AJNA BioSciences PBC | $2.1M | 57 | 506(b) | Jun 10, 2024 | 1 | direct |
| Aptevo Therapeutics Inc. | $2.1M | 11 | 506(c) | Apr 18, 2025 | 1 | direct |
| Vitalis Therapeutics, Inc. | $2.0M | 14 | 506(b) | Feb 19, 2025 | 1 | direct |
| Galenus Precision Pharmacy, Inc. | $1.9M | 20 | 506(b) | Feb 18, 2026 | 1 | direct |
| Dosentrx Ltd. | $1.8M | 17 | 506(b) | Mar 19, 2026 | 1 | direct |
| Cytogel Pharma, LLC | $1.8M | 18 | 506(b) | Oct 11, 2024 | 2 | direct |
| 60 DEGREES PHARMACEUTICALS, INC. | $1.8M | 10 | 506(b) | May 24, 2023 | 1 | direct |
| Scienture Holdings, Inc. | $1.7M | 8 | 506(b) | Aug 7, 2025 | 2 | direct |
| Seneca Therapeutics, Inc. | $1.6M | 68 | 506(b) | Feb 7, 2025 | 1 | direct |
| Revere Pharmaceuticals Inc. | $1.6M | 22 | 506(b) | Jun 12, 2023 | 1 | direct |
| Sea Pharmaceuticals, LLC | $1.5M | 27 | 506(b) | Jan 26, 2023 | 5 | direct |
| Plexiform Bioscience Inc. | $1.3M | 14 | 506(b) | Jul 18, 2025 | 2 | direct |
| Refuge Capital Fund | $1.2M | 20 | 506(b) | May 30, 2024 | 2 | direct |
| Lennham Pharmaceuticals, Inc. | $1.2M | 13 | 506(b) | Apr 4, 2023 | 1 | direct |
| Decoy Therapeutics, Inc. | $1.2M | 20 | 506(b) | Jul 14, 2025 | 2 | direct |
| DNA SEQ 2, INC. | $1.2M | 32 | 506(b) | Mar 11, 2026 | 1 | direct |
| RS BioTherapeutics Inc. | $1.1M | 5 | 506(b) | Oct 19, 2023 | 2 | direct |
| GreenJay Therapeutics, Inc. | $1.0M | 27 | 506(b) | Jun 16, 2023 | 1 | direct |
| Fidelis Animal Health Inc. | $1.0M | 10 | 506(b) | Feb 28, 2024 | 1 | direct |
| Enfuego Therapeutics, Inc. | $1.0M | 12 | 506(b) | Oct 28, 2025 | 2 | direct |
| Telomir Pharmaceuticals, Inc. | $1.0M | 10 | 506(b) | Apr 3, 2023 | 1 | direct |
| Centaur Bio Inc. | $1.0M | 26 | 506(b) | Sep 10, 2024 | 2 | direct |
| NOXX Therapeutics, Inc. | $1.0M | 11 | 506(b) | Mar 31, 2026 | 1 | direct |
| ABLi Therapeutics, Inc. | $1.0M | 10 | 506(b) | Jan 13, 2026 | 1 | direct |
